Pseudomonas aeruginosa

(redirected from P. aeruginosa)
Also found in: Encyclopedia.

Pseu·do·mo·nas ae·ru·gi·no·'sa

a bacterial species found in soil, water, and commonly in clinical specimens (wound infections, infected burn lesions, urinary tract infections); the causative agent of blue pus; occasionally pathogenic for plants; usually causes infections in humans in whom there is a defect in host defense mechanisms. It is the type species of the genus Pseudomonas.
Synonym(s): blue pus bacillus
Farlex Partner Medical Dictionary © Farlex 2012

pseudomonas aeruginosa

A normal soil inhabitant and human saprobe/commensal which may contaminate various solutions and fluids in a hospital, causing opportunistic infection in immunocompromised patients.
 
Clinical findings
Infective endocarditis in IV drug users, respiratory tract infections, urinary tract infections, bacteraemia, meningitis, “malignant” external otitis.

Management
Aminoglycosides—e.g., gentamicin, amikacin, netilmicin, tobramycin, etc. 

Pathogenesis
Pseudonomas aeruginosa is both invasive and toxicogenic, and infects patients in a 3-step process:
1. Bacterial attachment and colonization—mediated by pili and antiphagocytic effects of the organism’s polysaccharide capsule;
2. Local invasion—mediated by elastase and bacterial alkaline protease; and
3. Dissemination—high-dose tobramycin delivered by aerosol is reportedly effective in patients with cystic fibrosis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Pseudomonas aeruginosa

A normal soil inhabitant and human saprophyte that may contaminate various solutions in a hospital, causing opportunistic infection in weakened Pts Clinical Infective endocarditis in IVDAs, RTIs, UTIs, bacteremia, meningitis, 'malignant' external otitis Treatment Aminoglycosides–eg, gentamicin, amikacin, tobramycin, etc
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

Pseu·do·mo·nas ae·ru·gi·no·sa

(sū-dō-mōnăz ē-rū-ji-nōsă)
Bacterial species found in soil, water, and commonly in clinical specimens (wound infections, infected burn lesions, urinary tract infections); produces blue pus.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Enlarge picture
Psuedomonas Aeruginosa: infection of the distal foot

Pseudomonas aeruginosa

A species that produces a distinctive blue-green pigment, grows readily in water, and may cause life-threatening infections in humans, including nosocomial pneumonia, urinary tract infections, and sepsis. It may also cause folliculitis, malignant otitis externa, and skin infections in patients who have suffered burns. See: illustration
See also: Pseudomonas
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
This work aimed at studying the occurrence of P. aeruginosa in the water output of DUWLs in a dental center in Alexandria, Egypt.
Isolation of P. aeruginosa. Different strains of P.
It was reported that QnrA gene was detected in single FQnr isolate of P. aeruginosa. For this purpose, 256 isolates were tested against QnrA, QnrB, QnrC, QnrD and QnrS genes.
P. aeruginosa is frequently found in soil, water, plants, and moist environments.
P. aeruginosa has developed resistance to many antimicrobial agents including carbapenems, polymyxins, fluoroquinolones, cephalosporins, and aminoglycosides (Thabit et al., 2015).
The next resistance profile of the P. aeruginosa isolates was resistance to antibiotics in the cephalosporin class specifically 2nd- and 3rd generation cephalosporins including cefotaxime (81.4%), ceftazidime (60.5%), cefoxitin (55.8%) and ceftriaxone (48.8%).
The second would be a Phase 1/2 randomized, controlled clinical trial to evaluate the safety and efficacy of AB-PA01, administered intravenously with the best available antibiotic therapy, compared to placebo plus best available antibiotic therapy, in approximately 100 patients with P. aeruginosa bacteremia.
aureus ATCC (25923) 9 (*) 12 15 18 21 P. aeruginosa ATCC (27853) 6 6 9 (*) 11 14 E.
We conducted an epidemiologic investigation to establish the dynamic of carbapenem-resistant P. aeruginosa isolates in the household setting.
During July 13-September 22, 2017, six additional patients at the LTACH screened positive for VIM-producing P. aeruginosa during three biweekly point prevalence surveys and an enhanced prospective surveillance system (Figure).
The lasR gene codes the transcription factor, which is responsible for the activation of numerous target genes, most of them related to QS in P. aeruginosa. lasR mutations are diverse as well as the phenotypes generated by them.